Background: Stereotactic Ablative RadioTherapy (SABR) of lung tumors/metastases has been shown to be an effective treatment modality with low toxicity. Outcome and toxicity were retrospectively evaluated in a unique single-institution cohort treated with intensity-modulated image-guided breath-hold SABR (igSABR) without external immobilization. The dose-response relationship is analyzed based on Biologically Equivalent Dose (BED). Patients and methods: 50 lesions in 43 patients with primary NSCLC (n = 27) or lung-metastases of various primaries (n = 16) were consecutively treated with igSABR with Active-Breathing-Coordinator (ABC (R)) and repeat-breath-hold cone-beam-CT. After an initial dose-finding/-escalation period, 5x12 Gy for peripheral lesions and single doses of 5 Gy to varying dose levels for central lesions were applied. Overall-survival (OS), progression-free-survival (PFS), progression pattern, local control (LC) and toxicity were analyzed. Results: The median BED2 was 83 Gy. 12 lesions were treated with a BED2 of <80 Gy, and 38 lesions with a BED2 of >80 Gy. Median follow-up was 15 months. Actuarial 1- and 2-year OS were 67% and 43%; respectively. Cause of death was non-disease-related in 27%. Actuarial 1- and 2-year PFS was 42% and 28%. Progression site was predominantly distant. Actuarial 1- and 2 year LC was 90% and 85%. LC showed a trend for a correlation to BED2 (p = 0.1167). Pneumonitis requiring conservative treatment occurred in 23%. Conclusion: Intensity-modulated breath-hold igSABR results in high LC-rates and low toxicity in this unfavorable patient cohort with inoperable lung tumors or metastases. A BED2 of <80 Gy was associated with reduced local control.
|Data di pubblicazione:||2014|
|Titolo:||Clinical outcome of hypofractionated breath-hold image-guided SABR of primary lung tumors and lung metastases|
|Autore/i:||Boda-Heggemann, J; Frauenfeld, A; Weiss, C; Simeonova, A; Neumaier, C; Siebenlist, K; Attenberger, U; Heussel, Cp; Schneider, F; Wenz, F; Lohr, F|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.1186/1748-717X-9-10|
|Codice identificativo ISI:||WOS:000331625900002|
|Codice identificativo Scopus:||2-s2.0-84892188764|
|Codice identificativo Pubmed:||24401323|
|Citazione:||Clinical outcome of hypofractionated breath-hold image-guided SABR of primary lung tumors and lung metastases / Boda-Heggemann, J; Frauenfeld, A; Weiss, C; Simeonova, A; Neumaier, C; Siebenlist, K; Attenberger, U; Heussel, Cp; Schneider, F; Wenz, F; Lohr, F. - In: RADIATION ONCOLOGY. - ISSN 1748-717X. - 9(2014), pp. 1-9.|
|Tipologia||Articolo su rivista|
I documenti presenti in Iris Unimore sono rilasciati con licenza Creative Commons Attribuzione - Non commerciale - Non opere derivate 3.0 Italia, salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris